Longevity peptides, ranked by evidence
No compound in this library has been shown to extend human lifespan, because that trial has never been run on any of them. What the entries below have is mechanism, animal work, and in a few cases a marker that moved in a small human study.
- Compounds people use for this
- 11
- Approved for any indication
- 1
- Preliminary evidence or none
- 9
- Best-evidenced
- Elamipretide (SS-31)
A rank is a statement about evidence, not advice. Position here is calculated from the published evidence rating, regulatory standing and documented risks on each monograph. It says nothing about whether a compound is appropriate for you, and several of the best-evidenced entries are prescription medicines that carry serious warnings. Nothing on this page is a recommendation, and no page on this site states a dose.
A marker moving is not a life extended. Read what each study actually measured before reading anything into it.
Ranked by the same evidence score used across the site, restricted to the compounds people actually take for this. A compound near the bottom is not necessarily useless — it is untested, which is a different and more common situation. Every row links to a monograph that says exactly what was studied and in whom.
| # | Compound | Status | Evidenceout of 100 | Riskout of 100 | Gaprisk − evidence | Why it sits here |
|---|---|---|---|---|---|---|
| 1 | Elamipretide (SS-31) Longevity & Mitochondrial · SS-31 | FDA Approved | 78 | 36 | -42 | FDA Approved. 3 benefit claims on strong human evidence. 2 serious or common risks. |
| 2 | Sermorelin Growth Hormone Axis · GHRH (1-29) | Limited Approval | 54 | 43 | -11 | Limited Approval. 1 benefit claim on strong human evidence. 1 serious or common risk. |
| 3 | Thymalin Immune & Anti-inflammatory · Thymus extract peptide complex | Limited Approval | 37 | 65 | +28 | Limited Approval. No benefit claim on strong human evidence. 4 serious or common risks. |
| 4 | NAD+ (Nicotinamide Adenine Dinucleotide) Longevity & Mitochondrial · NAD | Not a Peptide | 32 | 83 | +51 | Not a Peptide. 1 benefit claim on strong human evidence. 4 serious or common risks. |
| 5 | Epitalon Longevity & Mitochondrial · Epithalon | Research Use Only | 30 | 81 | +51 | Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks. |
| 5 | Livagen Longevity & Mitochondrial · KEDA | Research Use Only | 30 | 91 | +61 | Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks. |
| 7 | Cartalax Healing & Tissue Repair · AED | Research Use Only | 15 | 95 | +80 | Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks. |
| 7 | FOXO4-DRI Longevity & Mitochondrial · FOXO4-p53 interfering peptide | Research Use Only | 15 | 82 | +67 | Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks. |
| 7 | GDF-11 Longevity & Mitochondrial · Growth Differentiation Factor 11 | Research Use Only | 15 | 89 | +74 | Research Use Only. No benefit claim on strong human evidence. 6 serious or common risks. |
| 7 | Humanin Longevity & Mitochondrial · HN | Research Use Only | 15 | 75 | +60 | Research Use Only. No benefit claim on strong human evidence. 3 serious or common risks. |
| 7 | MOTS-c Longevity & Mitochondrial · Mitochondrial ORF of the 12S rRNA type-c | Research Use Only | 15 | 97 | +82 | Research Use Only. No benefit claim on strong human evidence. 5 serious or common risks. |
How this ranking is built
| Evidence rating | 15 points each, up to 75 The published 1-5 rating, multiplied by fifteen. This is most of the score, because it is the thing the whole site is built to assess. |
|---|---|
| Regulatory standing | FDA Approved 12 · Limited Approval 7 · In Clinical Trials 4 · Cosmetic Ingredient 2 Approval by a major regulator means an agency has reviewed the trial data and agreed. Approval elsewhere, or an active registered trial, counts for less. A research-use-only label counts for nothing. |
| Well-supported benefit claims | 2 points each, up to 10 Two points for each benefit on the monograph carried by strong human evidence, up to five of them. A long list of weakly-supported claims adds nothing here. |
| Hard clinical endpoints | up to 3 Three points where a well-supported claim rests on something that happened to a patient — a death, a fracture, a heart attack, a transplant, a remission — rather than on a number that moved in a blood test. This is the site's published tie-breaker between two drugs that both have strong trials. |
Membership is computed from each monograph's category, tags and benefit claims rather than chosen by hand, so a compound added to the library appears here on its own. The score is the site-wide evidence score, not a score for this goal specifically — a compound approved for something else does not get credit here for that approval beyond its regulatory standing. Read the evidence scale for what the tiers mean.
The other things people ask about
See also the whole library ranked by evidence and by documented risk.